Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

USP9X destabilizes pVHL and promotes cell proliferation.

Zhang C, Peng Z, Zhu M, Wang P, Du X, Li X, Liu Y, Jin Y, McNutt MA, Yin Y.

Oncotarget. 2016 Sep 13;7(37):60519-60534. doi: 10.18632/oncotarget.11139.

2.

Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.

Jung YS, Lee SJ, Yoon MH, Ha NC, Park BJ.

Cell Cycle. 2012 Dec 1;11(23):4462-73. doi: 10.4161/cc.22794. Epub 2012 Nov 16.

3.

Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.

Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER.

Cancer Res. 2002 Jul 1;62(13):3803-11. Erratum in: Cancer Res. 2015 Sep 15;75(18):3993.

4.

VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.

Knauth K, Cartwright E, Freund S, Bycroft M, Buchberger A.

J Biol Chem. 2009 Apr 17;284(16):10514-22. doi: 10.1074/jbc.M809056200. Epub 2009 Feb 19.

5.

Parallel Regulation of von Hippel-Lindau Disease by pVHL-Mediated Degradation of B-Myb and Hypoxia-Inducible Factor α.

Okumura F, Uematsu K, Byrne SD, Hirano M, Joo-Okumura A, Nishikimi A, Shuin T, Fukui Y, Nakatsukasa K, Kamura T.

Mol Cell Biol. 2016 May 31;36(12):1803-17. doi: 10.1128/MCB.00067-16. Print 2016 Jun 15.

6.

The VHL tumor suppressor and HIF: insights from genetic studies in mice.

Kapitsinou PP, Haase VH.

Cell Death Differ. 2008 Apr;15(4):650-9. doi: 10.1038/sj.cdd.4402313. Epub 2008 Jan 25. Review.

7.
8.

pVHL mediates K63-linked ubiquitination of nCLU.

Xue J, Lv DD, Jiao S, Zhao W, Li X, Sun H, Yan B, Fan L, Hu RG, Fang J.

PLoS One. 2012;7(4):e35848. doi: 10.1371/journal.pone.0035848. Epub 2012 Apr 20.

9.

Effects of point mutations in pVHL on the binding of HIF-1α.

Domene C, Illingworth CJ.

Proteins. 2012 Mar;80(3):733-46. doi: 10.1002/prot.23230. Epub 2011 Nov 22.

PMID:
22105711
10.

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ.

Nature. 1999 May 20;399(6733):271-5.

PMID:
10353251
11.

Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor.

Liu W, Xin H, Eckert DT, Brown JA, Gnarra JR.

Oncogene. 2011 Jan 6;30(1):21-31. doi: 10.1038/onc.2010.395. Epub 2010 Aug 30.

12.

WSB1 promotes tumor metastasis by inducing pVHL degradation.

Kim JJ, Lee SB, Jang J, Yi SY, Kim SH, Han SA, Lee JM, Tong SY, Vincelette ND, Gao B, Yin P, Evans D, Choi DW, Qin B, Liu T, Zhang H, Deng M, Jen J, Zhang J, Wang L, Lou Z.

Genes Dev. 2015 Nov 1;29(21):2244-57. doi: 10.1101/gad.268128.115.

13.

Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein.

Nakamura E, Abreu-e-Lima P, Awakura Y, Inoue T, Kamoto T, Ogawa O, Kotani H, Manabe T, Zhang GJ, Kondo K, Nosé V, Kaelin WG Jr.

Am J Pathol. 2006 Feb;168(2):574-84.

14.

pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development.

Stickle NH, Chung J, Klco JM, Hill RP, Kaelin WG Jr, Ohh M.

Mol Cell Biol. 2004 Apr;24(8):3251-61.

15.

von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage.

Roe JS, Kim HR, Hwang IY, Cho EJ, Youn HD.

Oncogene. 2011 Jul 14;30(28):3127-38. doi: 10.1038/onc.2011.40. Epub 2011 Feb 28.

PMID:
21358672
16.

The von Hippel-Lindau tumor suppressor gene and kidney cancer.

Kaelin WG Jr.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6290S-5S. Review.

17.

Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.

Maynard MA, Ohh M.

Am J Nephrol. 2004 Jan-Feb;24(1):1-13. Epub 2003 Dec 3. Review.

18.

Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor.

Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G.

Biochem Biophys Res Commun. 2002 Jun 14;294(3):700-9.

PMID:
12056827
19.

Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein.

Li Z, Na X, Wang D, Schoen SR, Messing EM, Wu G.

J Biol Chem. 2002 Feb 15;277(7):4656-62. Epub 2001 Dec 5.

20.

Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.

Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH.

J Biol Chem. 2000 Aug 18;275(33):25733-41.

Supplemental Content

Support Center